Relationship of Body Adiposity with Platelet Function in Obese and Non-obese Individuals

Ishfaq A Bukhari1, Syed S Habib2, Alaa Alnahedh3

  • 1Pharmacology, College of Medicine, King Saud University, Riyadh, SAU.

Cureus
|March 6, 2020
PubMed

Insights

Obesity does not directly increase platelet activation, but waist-hip ratio (WHR) correlates with platelet aggregation, suggesting WHR may predict thromboembolism risk in obese individuals.

Area of Science:

  • Cardiovascular Science
  • Metabolic Health
  • Platelet Physiology

Background:

  • Adiposity is linked to cardiovascular and metabolic diseases like diabetes, hypertension, and thromboembolism.
  • Platelet hyperreactivity is a potential mechanism connecting obesity to these morbidities.
  • Understanding this link is crucial for risk assessment and prevention strategies.

Purpose of the Study:

  • To investigate the association between increased adiposity and platelet hyperreactivity in obese versus non-obese individuals.
  • To determine if body composition parameters correlate with platelet aggregation.
  • To identify potential markers for thromboembolism risk in obese populations.

Main Methods:

  • Cross-sectional study of 42 adults, categorized by body mass index (BMI) into obese and non-obese groups.
  • Data collection via questionnaires, body composition analysis, and blood sample processing for platelet-rich plasma (PRP).
  • Platelet aggregation induced by arachidonic acid and measured using a multichannel aggregation profiler.

Main Results:

  • Significant differences in body composition parameters (fat mass, body fat percentage, trunk fat, WHR, BMR) between obese and non-obese groups.
  • No significant difference in average platelet aggregation or area under the curve (AUC) between the groups.
  • Platelet function did not correlate with most body composition parameters, except for waist-hip ratio (WHR).

Conclusions:

  • Increased adiposity alone does not directly correlate with heightened platelet activation in obese individuals.
  • Waist-hip ratio (WHR) showed a significant positive correlation with the area under the curve for platelet aggregation.
  • WHR may serve as a valuable indicator for assessing thromboembolism risk in obese individuals.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
189
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
166
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
123
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K